In contrast, according to the Cancer Genome Atlas data, the mutation rate of TSC1/TSC2 was only 0.7% (P = 0.0004) in patients with HR+/HER2- early-stage breast cancer (84). The gene discussed is ERBB2; the disease is breast cancer.